A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression

NCT03044249 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

81

Enrollment

OTHER

Sponsor class

Stopped Statistical futility; totality of evidence suggests study unlikely to meet endpoint

Conditions

Psychosis
Dementia
Aggression
Agitation
Alzheimer Dementia

Interventions

DRUG: MP-101
DRUG: Placebo

Sponsor

Mediti Pharma Inc.